Veracyte delivered a robust performance in the second quarter of 2025, with total revenue increasing by 14% year-over-year to $130.2 million, driven primarily by a 14% rise in testing revenue. The company achieved a GAAP net loss of $1.0 million, which included $20.5 million in one-time impairment charges related to its French subsidiary, but reported a strong adjusted EBITDA of $35.8 million, representing 27.5% of revenue. Volume growth was also significant, with total test volume up 15% and testing volume up 18%.

Veracyte reported strong first quarter 2025 results driven by 22% total testing volume growth, leading to an 18% increase in total revenue to $114.5 million. Net income significantly improved to $7.0 million, and adjusted EBITDA grew 72% to $24.7 million.

Veracyte delivered strong financial results in Q4 2024, with total revenue increasing by 21% year-over-year to $118.6 million. The company's net income reached $5.1 million, compared to a net loss in the prior year. Adjusted EBITDA rose to $26.1 million, representing 22% of revenue. The testing business continued to drive growth, with a 24% increase in testing revenue and a 25% rise in testing volume. Looking ahead, Veracyte expects continued momentum in 2025, particularly in its Decipher and Afirma product lines.

Veracyte announced strong third-quarter results with a 29% increase in total revenue to $115.9 million and a 34% increase in testing revenue to $109.5 million. The company achieved profitability and cash generation, driven by growth in Decipher and Afirma tests. Veracyte is raising its full-year 2024 total revenue guidance to $442 million to $445 million.

Veracyte announced strong second quarter results with a 27% increase in total revenue to $114.4 million and a 31% increase in testing revenue. The company also reported net income of $5.7 million and adjusted EBITDA of $24.0 million, representing 21% of revenue. They raised full-year 2024 total revenue guidance to $432 million to $438 million.

Veracyte announced first quarter 2024 financial results with total revenue of $96.8 million, a 17% increase compared to the first quarter of 2023. Testing revenue grew by 25%, driven by the strong performance of Decipher Prostate and Afirma tests. The company raised its full-year 2024 total revenue guidance to $402 million to $410 million.

Veracyte announced a 22% increase in fourth-quarter revenue, reaching $98.2 million. The company's testing revenue grew by 29%, driven by the strong performance of Decipher Prostate and Afirma tests. Veracyte is focused on leveraging its Veracyte Diagnostics Platform to drive revenue growth and expects to achieve positive cash flow for the third consecutive year.

Veracyte announced a 19% increase in total revenue to $90.1 million for Q3 2023, driven by a 27% increase in testing revenue. The company raised its full-year 2023 total revenue guidance to $352 million to $354 million.

Veracyte announced outstanding second-quarter results, marked by a 24% increase in total revenue to $90.3 million and a 28% increase in total test volume to 31,809 compared to the second quarter of 2022. The company generated a record $17 million in cash from operations and raised its full-year 2023 total revenue guidance to $342 million to $350 million.

Veracyte reported strong first quarter results with revenue reaching $82.4 million, a 22% increase compared to Q1 2022. The company saw growth in Afirma and Decipher tests, maintained financial discipline, and ended the quarter with a robust cash balance. They are raising full-year 2023 total revenue guidance to $330 million to $340 million.

Veracyte announced strong Q4 2022 financial results, with revenue reaching $80.3 million, a 19% increase compared to the previous year. The company's Decipher and Afirma tests drove testing revenue growth. Veracyte is initiating 2023 annual total revenue guidance of $325 million to $335 million.

Veracyte reported a 25% increase in total revenue for Q3 2022, reaching $75.6 million. The company saw growth in test volume and expanded reimbursement contracts. They are raising full-year 2022 total revenue expectations to $288 million to $293 million.

Veracyte announced a 32% increase in total revenue to $72.9 million for the second quarter of 2022, driven by strong performance in testing revenue and the contribution of the HalioDx acquisition. The company also grew total test volume by 19% and ended the quarter with $164.0 million in cash, cash equivalents and short-term investments.

Veracyte reported an 85% increase in total revenue to $67.8 million for the first quarter of 2022, driven by strong performance in testing revenue and the contribution of the HalioDx acquisition.

Veracyte reported a 95% increase in revenue for Q4 2021, reaching $67.3 million. The company's net loss increased by 31% to $10.5 million, and basic and diluted net loss per common share increased by 7% to $0.15. Key business highlights included a 70% increase in test volume and the completion of the Decipher Biosciences and HalioDx acquisitions.

Veracyte reported a 94% increase in total revenue to $60.4 million for Q3 2021, including $4.7 million from the recently acquired HalioDx. The company launched the Percepta Nasal Swab and Decipher Bladder tests and completed the acquisition of HalioDx, contributing to its transformation into a global cancer diagnostics leader.

Veracyte announced strong second-quarter results with a 166% increase in total revenue to $55.1 million and a 215% increase in genomic volume to 20,856 tests. The company also raised its 2021 total revenue guidance and advanced its clinical evidence, pipeline, and global growth strategy.

Veracyte announced its Q1 2021 financial results, reporting a total revenue of $36.7 million, an 18% increase compared to the previous year. The company's genomic testing volume grew by 11% to 14,437 tests. Veracyte also completed the acquisition of Decipher Biosciences, expanding its reach into urologic cancer testing.

Veracyte announced a 16% increase in revenue to $34.5 million for the fourth quarter of 2020, with a 14% growth in genomic testing volume. The company is set to acquire Decipher Biosciences to expand its reach in cancer genomic diagnostics. Multiple new product launches are planned for 2021, including a noninvasive nasal swab test and Percepta Genomic Atlas in lung cancer.

Veracyte announced a strong rebound in business during the third quarter, with revenue returning to pre-pandemic levels at $31.1 million. The company achieved important reimbursement and clinical-evidence milestones and remains on track to launch four new clinical products in 2021.

Veracyte reported revenue of $20.7 million for the second quarter of 2020. The company's genomic testing volume saw a significant increase between April and June. They are on track to launch four new tests in 2021 and continued to grow biopharmaceutical and diagnostic partnerships.

Veracyte announced financial results for Q1 2020, featuring a 20% increase in total testing and product revenue to $30.4 million and a 15% growth in genomic testing volume. The company also secured strategic collaborations and advanced its pipeline.

Veracyte reported a 15% increase in total revenue for Q4 2019, reaching $29.7 million. The company achieved cash flow breakeven status and acquired global diagnostic rights to the NanoString nCounter FLEX Analysis System.